Does ayahuasca beat depression? Facts from recent clinical trials

Q: Is ayahuasca effective for treatment-resistant depression?

The strongest published evidence suggests it may be. The best-known placebo-controlled trial found stronger improvement with ayahuasca than placebo over the first week in patients with treatment-resistant depression.

Q: What did the NCT02914769 trial show on HAM-D and remission?

In the randomized trial, HAM-D response at day 7 was 57 percent with ayahuasca versus 20 percent with placebo, and HAM-D remission was 43 percent versus 13 percent.

Q: Is there a published ayahuasca vs esketamine trial?

Not yet. A direct comparison trial in major depression is registered as completed, but no published results paper was found.

April 4, 2026 at 3:03 am

Editorial illustration for an article on ayahuasca clinical trials and depression, showing a research desk, brain science motifs, and Amazonian plant elements in a calm, modern setting.

There is a reason this question keeps coming back.

When people have lived with depression for years, “maybe” starts to sound like hope. Maybe the standard antidepressants were too slow. Maybe talk therapy helped, but not enough. Maybe what looks like emotional numbness is really a nervous system stuck in the same loop, day after day.

That is why ayahuasca has moved from the edge of the conversation to the research table. Not because science has declared it a miracle, but because a small group of clinical studies has shown something psychiatry always takes seriously: a fast signal of change in people who often do not respond well to conventional treatment.

The honest version is less dramatic than the headlines. Ayahuasca has not “won” against depression. What it has done is earn a place in the serious research conversation. The published evidence is still small, the samples are still modest, and the field is waiting for direct comparisons with esketamine. But the early data are no longer easy to dismiss.

For readers looking for a more private and carefully structured format, this page explains how Amazonian solo retreats in Peru work, who they are designed for, and what an individual program includes from preparation to integration:

https://www.weles-group.com/projects/amazonian-solo-retreats/

Ayahuasca clinical trials for depression and PTSD: what the data show

Before the table, one important note: not every study below is a classic randomized clinical trial. That is part of the story. This field is still young, so the evidence ranges from open-label pilot work to one placebo-controlled depression trial, one PTSD case series, and two newly registered head-to-head studies against esketamine.

Study	Condition	Registry ID	Sample size	Design	Main outcome signal
Osório et al., 2015	Recurrent depression	Not identified in accessible primary sources	6	Open-label	Depressive scores fell significantly at 1, 7, and 21 days, with reductions reported up to 82%
Sanches et al., 2016	Recurrent depression	Not identified in accessible primary sources	17	Open-label SPECT study	Mean HAM-D dropped from 19.24 to 7.56 by day 21
Palhano-Fontes et al., 2019	Treatment-resistant depression	NCT02914769	29 analyzed	Randomized placebo-controlled	At day 7, HAM-D response was 57% vs 20% for placebo; HAM-D remission 43% vs 13%; MADRS response 64% vs 27%; MADRS remission 36% vs 7%
Weiss et al., 2024	PTSD in veterans	Not identified in accessible primary sources	8	Mixed-methods case series	5 of 7 veterans showed reliable PCL-5 improvement after treatment, maintained at 3 months
Ayahuasca and Esketamine for Major Depression	Severe major depression	NCT07212946	22 actual	Double-blind randomized	Completed; registry lists Beck Depression Inventory at 49 days as the primary outcome, but no published results found yet
Ayahuasca, Esketamine and PTSD	PTSD	NCT07317206	10 estimated	Randomized	Recruiting; primary outcome is PCL-5 over 3 weeks, no results yet

What the ayahuasca depression data mean in real life

The strongest published clinical result is still the placebo-controlled trial in treatment-resistant depression. That matters because treatment-resistant depression is not mild sadness. It usually means a person has already tried more than one standard option and still feels trapped.

In plain language, the result was this: one ayahuasca session outperformed placebo across the first week, and by day 7 the gap was meaningful on both clinician-rated and patient-relevant depression measures. That does not prove long-term recovery. It does show that ayahuasca can produce a rapid antidepressant signal strong enough to show up even in a difficult patient group.

The older open-label studies matter for another reason. They tell us the signal was not born in one lucky trial. Small groups of patients with recurrent depression also showed noticeable improvement within days, with benefits lasting out to three weeks in the published follow-up window. Open-label research is easier to overestimate, but it still helped build the case that this was worth testing under stricter conditions.

The PTSD side is weaker. The 2024 veteran case series is interesting, especially because the changes were not just abstract questionnaire shifts: several participants showed clinically meaningful improvement that lasted to three months. But this was not a blinded randomized PTSD trial. It is a signal, not a verdict.

How ayahuasca may work: 5-HT2A, DMT, MAO-A, and mood flexibility

If the chemistry sounds intimidating, the logic is simple.

Ayahuasca combines DMT with beta-carbolines such as harmine, which slow the breakdown of DMT by inhibiting MAO-A. DMT is thought to produce much of the acute psychedelic effect through serotonin signaling, especially at the 5-HT2A receptor, while ayahuasca’s full pharmacology appears broader than one receptor alone. Human and preclinical work suggests this receptor system is central to the shift in perception, emotion, and cognitive flexibility people report during the acute experience.

That still leaves the antidepressant question. One of the more interesting mechanistic findings from the randomized ayahuasca trial was the link between clinical improvement and biological markers such as BDNF and cortisol. In simple terms, the brew may be doing more than creating an intense experience. It may also be interacting with stress-regulation and neuroplasticity pathways that matter in depression. That is not proof of a single “depression switch,” but it helps explain why the effect may feel fast in some patients.

Think of a person whose depression is less like sadness and more like mental gridlock. Same thoughts. Same dead ends. Same bodily heaviness every morning. A 5-HT2A-driven psychedelic intervention may, for some people, briefly loosen that locked pattern. The promise is not ecstasy. The promise is movement. That is a more accurate way to describe what the clinical field is testing. This framing is an inference from the mechanism and trial data, not a direct quote from any one study.

Ayahuasca vs esketamine: a fair comparison, or too early?

This is where a lot of writing gets sloppy.

Esketamine already has a much larger evidence base in treatment-resistant depression than ayahuasca. Recent meta-analytic work supports significant reductions in MADRS scores and improved response rates with esketamine nasal spray, while remission findings remain less consistent. In other words, esketamine is not perfect, but it is far further down the clinical road.

Ayahuasca has a stronger “novelty” pull, but a thinner evidence file. That is why the two São Paulo registry entries matter so much. NCT07212946 is the first especially relevant direct comparison in severe major depression, and NCT07317206 extends that comparison into PTSD. Until those results are published, any confident claim that ayahuasca works better than esketamine is marketing, not science.

Who may fit the research profile for ayahuasca treatment

The research profile is narrower than the internet usually suggests.

Published depression studies focused on adults with clinically significant depression, often recurrent or treatment-resistant, who were medically screened and excluded for major psychiatric or medical risks. Pregnancy, bipolar disorder, psychosis history, major neurological disease, and substance misuse were commonly treated as reasons for exclusion. That does not mean ayahuasca has no value outside research settings. It means the evidence we do have comes from selected groups, not from “everyone with low mood.”

So who fits the research profile best? Usually someone with substantial depressive symptoms, poor response to previous care, and enough clinical stability to tolerate a highly intense intervention in a structured setting. Who does not fit well? Someone looking for a shortcut, someone with major contraindications, or someone who hears “fast-acting” and assumes “easy.” The trials do not support that fantasy.

Ethics: hope without hype

This is the part that decides whether this field matures well.

Ayahuasca research brings together medicine, culture, commerce, and desperation. That is powerful, and it can also get messy. Small samples tend to produce oversized headlines. Psychedelic experiences are hard to blind cleanly. Retreat settings mix pharmacology with expectation, group process, ritual, and support. That makes the data more human, but also harder to interpret.

The ethical standard should be simple: respect the signal, do not inflate it. A fast antidepressant effect is clinically meaningful. It is not the same as a cure. A moving personal story is valuable. It is not the same as a replicated randomized result. And traditional knowledge deserves respect without being turned into either mysticism for sale or a laboratory prop stripped of context.

Bottom line: what fresh ayahuasca trials really tell us

Ayahuasca has not conquered depression. But it has crossed an important line: it now has enough human clinical data to be discussed seriously, not just symbolically.

The best published evidence suggests a real rapid antidepressant signal, especially in treatment-resistant depression. The PTSD evidence is still preliminary. The direct comparison with esketamine is finally being tested, but the results are not public yet. So the most accurate conclusion is not triumph or dismissal. It is this: ayahuasca is one of the more compelling early-stage antidepressant stories in psychiatry, and the next few published trials will decide whether that story becomes a treatment pathway or stays a promising outlier.

FAQ

1. Is ayahuasca effective for treatment-resistant depression?

The strongest published evidence says it may be. The best-known placebo-controlled trial found stronger improvement with ayahuasca than placebo over the first week in patients with treatment-resistant depression.

2. How fast can ayahuasca work in depression studies?

Published studies suggest changes can appear within 1 to 7 days, which is one reason ayahuasca is discussed as a rapid-acting antidepressant candidate.

3. What did the NCT02914769 trial show on HAM-D and remission?

In the randomized trial, HAM-D response at day 7 was 57% with ayahuasca versus 20% with placebo, and HAM-D remission was 43% versus 13%.

4. Is there a published ayahuasca vs esketamine trial?

Not yet, based on the sources I found. A direct comparison trial in major depression is registered as completed, but I did not find a published results paper.

5. Has ayahuasca been tested for PTSD?

Yes, but the published human evidence is still preliminary. The main published PTSD study I found was a small veteran case series, not a full randomized controlled trial.

6. How does ayahuasca affect the 5-HT2A receptor?

DMT, the main psychedelic compound in ayahuasca, is believed to act importantly through serotonin 5-HT2A signaling, while harmine and related compounds help make oral DMT active by inhibiting MAO-A.

7. Is ayahuasca just the same thing as DMT?

No. DMT is one key component, but ayahuasca is a brew with a combined pharmacology. The MAO-inhibiting beta-carbolines change how DMT is absorbed and experienced.

8. Who was usually excluded from ayahuasca depression trials?

Typical exclusions included pregnancy, psychosis history, bipolar disorder, major neurological illness, and significant medical or substance-related risks.

9. Is ayahuasca better than esketamine?

There is not enough published direct evidence to say that. Esketamine has a broader and more mature evidence base, while ayahuasca remains earlier-stage and less replicated.

10. What is the biggest limitation of ayahuasca clinical research?

Small samples. Most published ayahuasca studies in depression and PTSD remain small, and that makes both overstatement and underestimation possible.

The Personal Retreat Brief is the starting point of the process: a confidential intake form used to shape a retreat protocol around your situation, intentions, safety considerations, and readiness for solo work in the Peruvian Amazon:

https://www.weles-group.com/personal-retreat-brief/